Annals of Oncology 13:222-228, 2002
© 2002 European Society for Medical Oncology
Long-term renal function after treatment for malignant germ-cell tumours
Departments of 1Medical Oncology and Radiotherapy, 2Nuclear Medicine and 4Medical Physics, and 3Central Laboratory, The Norwegian Radium Hospital, Montebello, 0310 Oslo, Norway
Received 25 June 2001; revised 11 September 2001; accepted 19 September 2001.
Objective
To evaluate prospectively renal function in patients with malignant germ-cell tumours (MGCTs) >10 years after retroperitoneal lymph node dissection alone (RPLND), radiotherapy alone (RAD) or different schedules of cisplatin-based chemotherapy with or without surgery/radiotherapy (CHEM).
Patients and methods
In 85 patients, three groups were identified: RPLND, 14; RAD, 18; CHEM, 53, with subdivision of the latter group according to the cumulative cisplatin dose or the additional use of radiotherapy. Renal function was determined by 131Iodine Hippuran clearance or 99m DTPA glomerular filtration rate, and was assessed before treatment and four times during 14 years of follow-up. A value of <70% of the upper limit of the normal range identified impaired renal function.
Results
Twenty-five patients displayed long-term impaired renal function, 23 of them from the RAD or CHEM group. In the RAD group, renal function decreased by 8%, whereas a 14% reduction of renal function was observed in the CHEM group. In the CHEM group the cumulative dose of cisplatin, and in the RAD group the age at treatment, were associated with impairment of renal function. Combining all patients, age at treatment and the type of treatment were associated with impaired renal function.
Conclusions
In 20–30% of the patients with germ-cell tumour, standard radiotherapy and chemotherapy strategies are followed by long-term subclinical impaired renal function. These findings support current intentions to avoid overtreatment with these treatment modalities.
Key words: long-term renal function, testicular cancer, treatment
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. Kollmannsberger, C. Moore, K. N. Chi, N. Murray, S. Daneshmand, M. Gleave, B. Hayes-Lattin, and C.R. Nichols Non-risk-adapted surveillance for patients with stage I nonseminomatous testicular germ-cell tumors: diminishing treatment-related morbidity while maintaining efficacy Ann. Onc., October 29, 2009; (2009) mdp473v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. R. Feldman, G. J. Bosl, J. Sheinfeld, and R. J. Motzer Medical Treatment of Advanced Testicular Cancer JAMA, February 13, 2008; 299(6): 672 - 684. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Haugnes, N Aass, S. Fossa, O Dahl, O Klepp, E. Wist, J Svartberg, T Wilsgaard, and R. Bremnes Components of the metabolic syndrome in long-term survivors of testicular cancer Ann. Onc., February 1, 2007; 18(2): 241 - 248. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Sagstuen, N. Aass, S.D. Fossa, O. Dahl, O. Klepp, E.A. Wist, T. Wilsgaard, and R.M. Bremnes Blood Pressure and Body Mass Index in Long-Term Survivors of Testicular Cancer J. Clin. Oncol., August 1, 2005; 23(22): 4980 - 4990. [Abstract] [Full Text] [PDF]
|
|